April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 29, 2025

Progression in Parkinson’s

α-Synuclein PET tracer shows potential to diagnose and monitor the disease

The Pathologist

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 21, 2025

Transfusion Strategy Outcomes After Aneurysmal SAH Similar, Study Reveals

SAHaRA trial investigators compared a liberal (transfusion at hemoglobin levels of 10 g/dL or lower) and a restrictive (transfusion at 8 g/dL or lower) red-cell tranfusion strategy among critically ill patients with acute aneurysmal subarachnoid hemorrhage (SAH) and anemia.

Conexiant

April 18, 2025

Intranasal Diazepam Gains Expanded Approval for Pediatric Patients

“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”

Conexiant

April 17, 2025

Climate Identified as Key Virus Driver

Researchers found Oropouche virus to be underreported during a large-scale study across Latin America, with climate emerging as the primary driver of transmission risk.

Conexiant

April 17, 2025

We Want Your Perspective!

Join our roster of respected specialists and share your clinical perspectives.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 14, 2025

Inebilizumab Effective for Myasthenia Gravis

CD19+ B-cell-depleting therapy shows significant improvement in function and disease severity in phase III trial of autoimmune neuromuscular disorder.

Conexiant